Enhancing Triple Negative Breast Cancer Immunotherapy by ICG-Templated Self-Assembly of Paclitaxel Nanoparticles

被引:184
|
作者
Feng, Bing [1 ,2 ,3 ]
Niu, Zifei [1 ,2 ]
Hou, Bo [1 ,2 ]
Zhou, Lei [1 ,2 ]
Li, Yaping [1 ,2 ,3 ]
Yu, Haijun [1 ,2 ,3 ]
机构
[1] Chinese Acad Sci, State Key Lab Drug Res, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China
[2] Chinese Acad Sci, Ctr Pharmaceut, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China
[3] Univ Chinese Acad Sci, Beijing 100049, Peoples R China
基金
中国国家自然科学基金;
关键词
immune checkpoint blockade; immunogenic cell death; immunotherapy; self-assemble; triple negative breast cancer; CARRIER-FREE; PHOTODYNAMIC THERAPY; PD-L1; EXPRESSION; CELL; CHEMOTHERAPY; BLOCKADE; DELIVERY;
D O I
10.1002/adfm.201906605
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Combination cancer immunotherapy has shown promising potential for simultaneously eliciting antitumor immunity and modulating the immunosuppressive tumor microenvironment (ITM). However, combination immunotherapy with multiple regimens suffers from the varied chemo-physical properties and inconsistent pharmacokinetic profiles of the different therapeutics. To achieve tumor-specific codelivery of the immune modulators, an indocyanine green (ICG)-templated self-assembly strategy for preparing dual drug-loaded two-in-one nanomedicine is reported. ICG-templated self-assembly of paclitaxel (PTX) nanoparticles (ISPN), and the application of ISPN for combination immunotherapy of the triple negative breast cancer (TNBC) are demonstrated. The ISPN show satisfied colloidal stability and high efficacy for tumor-specific codelivery of ICG and PTX through the enhanced tumor permeability and retention effect. Upon laser irradiation, the ICG component of ISPN highly efficiently induces immunogenic cell death of the tumor cells via activating antitumor immune response through photodynamic therapy. Meanwhile, PTX delivered by ISPN suppresses the regulatory T lymphocytes (T-regs) to combat ITM. The combination treatment of TNBC with ISPN and alpha PD-L1-medaited immune checkpoint blockade therapy displays a synergistic effect on tumor regression, metastasis inhibition, and recurrence prevention. Overall, the ICG-templated nanomedicine may represent a robust nanoplatform for combination immunotherapy.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Role of Immunotherapy in Triple-Negative Breast Cancer
    Keenan, Tanya E.
    Tolaney, Sara M.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (04): : 479 - 489
  • [22] Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer
    Zheng, Yiwen
    Li, Shujin
    Tang, Hongchao
    Meng, Xuli
    Zheng, Qinghui
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [23] Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer
    Agostinetto, Elisa
    Losurdo, Agnese
    Nader-Marta, Guilherme
    Santoro, Armando
    Punie, Kevin
    Barroso, Romualdo
    Popovic, Lazar
    Solinas, Cinzia
    Kok, Marleen
    de Azambuja, Evandro
    Lambertini, Matteo
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2022, 31 (06) : 567 - 591
  • [24] Gold Nanoparticles in Triple-Negative Breast Cancer Therapeutics
    Akter, Zakia
    Khan, Fabiha Zaheen
    Khan, Md. Asaduzzaman
    CURRENT MEDICINAL CHEMISTRY, 2023, 30 (03) : 316 - 334
  • [25] Enhanced Therapeutic Efficacy of Combining Losartan and Chemo-Immunotherapy for Triple Negative Breast Cancer
    Zhao, Qing
    He, Xuexin
    Qin, Xiyi
    Liu, Yu
    Jiang, Han
    Wang, Jing
    Wu, Shuang
    Zhou, Rui
    Yu, Congcong
    Liu, Suling
    Zhang, Hong
    Tian, Mei
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [26] Trials of Immunotherapy in Triple Negative Breast Cancer
    Ozge Gumusay
    Chiara A. Wabl
    Hope S. Rugo
    Current Breast Cancer Reports, 2021, 13 : 171 - 185
  • [27] Modern Immunotherapy in the Treatment of Triple-Negative Breast Cancer
    Wesolowski, Jakub
    Tankiewicz-Kwedlo, Anna
    Pawlak, Dariusz
    CANCERS, 2022, 14 (16)
  • [28] Immunotherapy in Triple-Negative Breast Cancer: Present and Future
    Isaac Kim
    Katherine Sanchez
    Heather L. McArthur
    David Page
    Current Breast Cancer Reports, 2019, 11 : 259 - 271
  • [29] Recent advances in triple negative breast cancer: the immunotherapy era
    Antonio Marra
    Giulia Viale
    Giuseppe Curigliano
    BMC Medicine, 17
  • [30] HDAC inhibition potentiates immunotherapy in triple negative breast cancer
    Terranova-Barberio, Manuela
    Thomas, Scott
    Ali, Niwa
    Pawlowska, Nela
    Park, Jeenah
    Krings, Gregor
    Rosenblum, Michael D.
    Budillon, Alfredo
    Munster, Pamela N.
    ONCOTARGET, 2017, 8 (69) : 114156 - 114172